List today: 89bio, Inc. ETNB is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 38.8% downward over the last 60 days. Altice USA ...

Check the time stamp on this data. Updated AI-Generated Signals for 89bio Inc. (ETNB) available here: ETNB. Type a few ...

After reaching an important support level, 89BIO (ETNB) could be a good stock pick from a technical perspective. ETNB surpassed resistance at the 20-day moving average, suggesting a short-term ...

Inc. (NASDAQ:ETNB – Get Free Report)’s share price dropped 3.7% during trading on Tuesday . The company traded as low as $7.50 and last traded at $7.50. Approximately 101,562 shares were traded during ...

(NASDAQ:ETNB – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor ...

SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target of $29.00. The ...

In this article, we are going to take a look at where 89bio, Inc. (NASDAQ:ETNB) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of ...

New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpointsSAN FRANCISCO, Nov. 15, 2024 ...